Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel Oral Suspension as Adjunctive Therapy in Young Children With Epilepsy
ChiCTR2500109538Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perampanel in epilepsy, sponsored by Peking University First Hospital. Primary endpoint: 50% responder rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on ChiCTR2500109538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109538.